EP1431293A4 - Wasserlösliche phenylpyridazinderivate und diese enthaltende arzneimittel - Google Patents

Wasserlösliche phenylpyridazinderivate und diese enthaltende arzneimittel

Info

Publication number: EP1431293A4
Authority: EP; European Patent Office
Prior art keywords: alkyl; water; group; medicaments containing; compounds
Prior art date: 2001-09-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP02768055A

Other languages

English (en)

French (fr)

Other versions

EP1431293B1 (de

EP1431293A1 (de

Inventor

Yoshinori Kyotani

Tomoyuki Koshi

Hiromichi Shigyo

Hideo Yoshizaki

Takahiro Kitamura

Shunji Takemura

Kyoko Yasuoka

Junko Totsuka

Seiichi Sato

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kowa Co Ltd

Original Assignee

Kowa Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-26

Filing date

2002-09-25

Publication date

2004-12-22

2002-09-25 Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd

2004-06-23 Publication of EP1431293A1 publication Critical patent/EP1431293A1/de

2004-12-22 Publication of EP1431293A4 publication Critical patent/EP1431293A4/de

2011-06-08 Application granted granted Critical

2011-06-08 Publication of EP1431293B1 publication Critical patent/EP1431293B1/de

2022-09-25 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

EP02768055A 2001-09-26 2002-09-25 Wasserlösliche phenylpyridazinderivate und diese enthaltende arzneimittel Expired - Lifetime EP1431293B1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US32456901P	2001-09-26	2001-09-26
US324569P		2001-09-26
PCT/JP2002/009863 WO2003027077A1 (en)	2001-09-26	2002-09-25	Water-soluble phenylpyridazine derivatives and drugs containing the same

Publications (3)

Publication Number	Publication Date
EP1431293A1 EP1431293A1 (de)	2004-06-23
EP1431293A4 true EP1431293A4 (de)	2004-12-22
EP1431293B1 EP1431293B1 (de)	2011-06-08

Family

ID=23264178

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP02768055A Expired - Lifetime EP1431293B1 (de)	2001-09-26	2002-09-25	Wasserlösliche phenylpyridazinderivate und diese enthaltende arzneimittel

Country Status (16)

Country	Link
US (2)	US6869954B2 (de)
EP (1)	EP1431293B1 (de)
JP (1)	JP4280165B2 (de)
KR (1)	KR20040039377A (de)
CN (1)	CN1304379C (de)
AT (1)	ATE512139T1 (de)
AU (1)	AU2002332286B2 (de)
BR (1)	BR0212848A (de)
CA (1)	CA2461806A1 (de)
HU (1)	HUP0402149A3 (de)
MX (1)	MXPA04002939A (de)
NO (1)	NO327425B1 (de)
NZ (1)	NZ531982A (de)
PL (1)	PL368340A1 (de)
RU (1)	RU2302413C2 (de)
WO (1)	WO2003027077A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1602655A4 (de) *	2003-03-07	2010-06-09	Kowa Co	Benzofuranderivat
BRPI0408359A (pt) *	2003-03-18	2006-03-21	Kowa Co	derivados de fenilpiridazina solúveis em água e medicamentos contendo os mesmos
WO2021124346A1 (en) *	2019-12-18	2021-06-24	Abida /	Novel 4-(6-oxo-3-substituted phenylpyridazin-1(6 h)-yl)benzaldehydes of pharmaceutical interest
GB202311227D0 (en) *	2023-07-21	2023-09-06	Almac Discovery Ltd	Pharmaceutical compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0537696A1 (de) *	1991-10-18	1993-04-21	Dr. Karl Thomae GmbH	Heterobiarylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4404203A (en) *	1981-05-14	1983-09-13	Warner-Lambert Company	Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
CA2283399C (en) *	1997-03-14	2006-02-21	Merck Frosst Canada & Co.	Pyridazinones as inhibitors of cyclooxygenase-2
EP2017266A1 (de) *	1997-11-19	2009-01-21	Kowa Co., Ltd.	Pyridazinderivate und diese als aktiven Bestandteil enthaltende Medikamente
TWI241295B (en) *	1998-03-02	2005-10-11	Kowa Co	Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja)	1999-02-26	2000-09-12	Kowa Co	ピリダジン−３−オン誘導体及びこれを含有する医薬
US6664256B1 (en)	2000-07-10	2003-12-16	Kowa Co., Ltd.	Phenylpyridazine compounds and medicines containing the same
CA2742411A1 (en) *	2000-09-18	2002-03-21	Eisai R&D Management Co., Ltd.	Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations
US6861428B2 (en)	2001-09-26	2005-03-01	Kowa Co., Ltd.	Water-soluble phenylpyridazine compounds and compositions containing the same

2002
- 2002-09-25 AU AU2002332286A patent/AU2002332286B2/en not_active Ceased
- 2002-09-25 US US10/253,523 patent/US6869954B2/en not_active Expired - Fee Related
- 2002-09-25 JP JP2003530668A patent/JP4280165B2/ja not_active Expired - Lifetime
- 2002-09-25 MX MXPA04002939A patent/MXPA04002939A/es active IP Right Grant
- 2002-09-25 CN CNB02818940XA patent/CN1304379C/zh not_active Expired - Fee Related
- 2002-09-25 WO PCT/JP2002/009863 patent/WO2003027077A1/ja not_active Ceased
- 2002-09-25 BR BR0212848-9A patent/BR0212848A/pt not_active IP Right Cessation
- 2002-09-25 KR KR10-2004-7003995A patent/KR20040039377A/ko not_active Ceased
- 2002-09-25 CA CA002461806A patent/CA2461806A1/en not_active Abandoned
- 2002-09-25 RU RU2004112532/04A patent/RU2302413C2/ru not_active IP Right Cessation
- 2002-09-25 PL PL02368340A patent/PL368340A1/xx not_active Application Discontinuation
- 2002-09-25 NZ NZ531982A patent/NZ531982A/en not_active IP Right Cessation
- 2002-09-25 AT AT02768055T patent/ATE512139T1/de not_active IP Right Cessation
- 2002-09-25 HU HU0402149A patent/HUP0402149A3/hu unknown
- 2002-09-25 EP EP02768055A patent/EP1431293B1/de not_active Expired - Lifetime
2004
- 2004-03-25 NO NO20041250A patent/NO327425B1/no not_active IP Right Cessation
- 2004-10-12 US US10/960,993 patent/US7087606B2/en not_active Expired - Fee Related

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0537696A1 (de) *	1991-10-18	1993-04-21	Dr. Karl Thomae GmbH	Heterobiarylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Also Published As

Publication number	Publication date
MXPA04002939A (es)	2004-06-18
AU2002332286B2 (en)	2007-10-18
HUP0402149A3 (en)	2005-08-29
US20050085480A1 (en)	2005-04-21
NZ531982A (en)	2005-08-26
PL368340A1 (en)	2005-03-21
US6869954B2 (en)	2005-03-22
HUP0402149A2 (hu)	2005-02-28
WO2003027077A1 (en)	2003-04-03
ATE512139T1 (de)	2011-06-15
US7087606B2 (en)	2006-08-08
BR0212848A (pt)	2004-08-17
CA2461806A1 (en)	2003-04-03
EP1431293B1 (de)	2011-06-08
EP1431293A1 (de)	2004-06-23
CN1304379C (zh)	2007-03-14
US20030119838A1 (en)	2003-06-26
RU2302413C2 (ru)	2007-07-10
NO20041250L (no)	2004-03-25
HK1070068A1 (en)	2005-06-10
JPWO2003027077A1 (ja)	2005-01-06
NO327425B1 (no)	2009-06-29
CN1558903A (zh)	2004-12-29
KR20040039377A (ko)	2004-05-10
JP4280165B2 (ja)	2009-06-17
RU2004112532A (ru)	2005-03-27

Legal Events

Date	Code	Title	Description
2004-05-07	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2004-06-23	17P	Request for examination filed	Effective date: 20040324
2004-06-23	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
2004-06-23	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO SI
2004-12-22	A4	Supplementary search report drawn up and despatched	Effective date: 20041105
2004-12-22	RIC1	Information provided on ipc code assigned before grant	Ipc: 7A 61K 31/50 B Ipc: 7C 07D 237/14 A Ipc: 7A 61P 29/00 B
2008-10-29	17Q	First examination report despatched	Effective date: 20080930
2010-09-07	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2011-01-28	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2011-05-06	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2011-06-08	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
2011-06-08	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2011-06-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: NV Representative=s name: BOVARD AG
2011-07-06	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2011-07-21	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 60240240 Country of ref document: DE Effective date: 20110721
2011-09-28	REG	Reference to a national code	Ref country code: NL Ref legal event code: VDEP Effective date: 20110608
2011-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110608
2011-10-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20110926 Year of fee payment: 10
2011-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110608 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110608 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110909 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110608 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110919
2011-11-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20110830 Year of fee payment: 10 Ref country code: GB Payment date: 20110923 Year of fee payment: 10 Ref country code: FR Payment date: 20111005 Year of fee payment: 10
2011-12-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110608 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110608
2012-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111010 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110608 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110608
2012-02-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110608
2012-04-13	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2012-04-13	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2012-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110930
2012-05-16	26N	No opposition filed	Effective date: 20120309
2012-06-20	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2012-06-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110608
2012-07-12	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 60240240 Country of ref document: DE Effective date: 20120309
2012-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110925
2013-04-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2013-05-29	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20120925
2013-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110925
2013-06-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110908
2013-06-28	REG	Reference to a national code	Ref country code: FR Ref legal event code: ST Effective date: 20130531
2013-07-25	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 60240240 Country of ref document: DE Effective date: 20130403
2013-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120925 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120930 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120930 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130403
2013-08-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121001 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120925
2013-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110608

Publication	Publication Date	Title
DE60140456D1 (de)	2009-12-24	Aza heterocyclische derivate und ihre therapeutische verwendung
NO20012617L (no)	2001-09-14	Kinolin- og kinzolinderivater
SG128491A1 (en)	2007-01-30	Heterocyclic sulfonamide inhibitors of beta amyloid production
FI953968A0 (fi)	1995-08-23	Antraniiliset happojohdannaiset
TR200200579T2 (tr)	2002-12-23	Amino-tirazolpiridin türevleri.
NO20015172L (no)	2002-01-23	1-metyl-erytromycin-derivater
CY1111816T1 (el)	2015-10-07	Παραγωγο θειαδιαζολινης για την θεραπεια του καρκινου
EP1156045A4 (de)	2002-04-17	Amid-derivate und drogen-zusammensetzungen
EP1300399A4 (de)	2004-02-11	Phenylpyridazinderivate und diese enthaltende arzneimittel
NO20022470D0 (no)	2002-05-24	Pyrimidinderivater
PT992509E (pt)	2004-12-31	Novos derivados macrolidos
DE60105610D1 (en)	2004-10-21	Pyrazinonderivate
MXPA02004441A (es)	2004-09-10	Derivados de isoxazol como inhibidores de la fosfodiesterasa.
PL368340A1 (en)	2005-03-21	Water-soluble phenylpyridazine derivatives and drugs containing the same
ATE214064T1 (de)	2002-03-15	Indane-1-ol derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
AP2002002595A0 (en)	2002-09-30	Heterocyclic amide derivatives.
HUP0202438A2 (hu)	2002-12-28	Dioxo-tiazolidin-származékok és ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
ATE552003T1 (de)	2012-04-15	Chinoxalinderivate
DK0952157T3 (da)	2003-10-13	9a, 11b-dehydroderivater af 9-oxim-3-keto-6-0-methylerythromycin
ATE262522T1 (de)	2004-04-15	Benzimidazolverbindungen
TH67630A (th)	2005-02-25	อินโดล, อะซาอินโดล และเฮเทอโรไซคลิก 4- แอลคีนิลพิเพอริดีนเอไมด์ที่เกี่ยวข้อง